Blog

INTEREST 2024 KEY TAKEAWAYS

Last week, MOSAIC staff from Nigeria traveled to Cotonou, Benin, for the International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST). They participated in the conference in person and, in this post, share their reflections.

Continue Reading

Blog

JUMP-STARTING PrEP INTRODUCTION: LEVERAGING MOSAIC’S TEMPLATE GUIDELINES TO CREATE AN ENABLING POLICY ENVIRONMENT

When a country is poised to introduce a new biomedical prevention product, policymakers want to ensure that their rollout plan is based on the latest science and provides clear, standardized procedures for implementation. The WHO publishes global guidance on delivering new HIV prevention products, but those recommendations need to be adapted to the local context. 

Continue Reading

Blog

YOUTH-POWERED: THREE WAYS THE CATALYST STUDY ENGAGES YOUNG WOMEN TO UNDERSTAND PrEP CHOICE

What sets CATALYST apart is the study’s emphasis on meaningful involvement of young people at every stage of the research to understand end-user perspectives and help tailor the study to meet their needs. This makes us hopeful because the inclusion of young people in the CATALYST journey has not been tokenistic; rather our contributions have been reflected in the whole process so far. In this post, we describe three ways youth have been engaged in CATALYST.

Continue Reading

Blog

CONFERENCE REFLECTIONS: TWO CROI “ROOKIES” DRAW INSPIRATION FROM CROI AT 30

CROI is a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases, including HIV and AIDS. It was the 30th year of the conference, but our first time attending. In this post, we reflect on what we learned and how we might apply key takeaways to our work on MOSAIC.

Continue Reading

Events

CHAMPIONING CHOICE IN A MULTI-PRODUCT HIV PREVENTION MARKET

New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.

Continue Reading